Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)

被引:183
作者
Bergman, PJ
MacEwen, EG
Kurzman, ID
Henry, CJ
Hammer, AS
Knapp, DW
Hale, A
Kruth, SA
Klein, MK
Klausner, J
Norris, AM
McCaw, D
Straw, RC
Withrow, SJ
机构
[1] COLORADO STATE UNIV,FT COLLINS,CO 80523
[2] UNIV WISCONSIN,MADISON,WI
[3] AUBURN UNIV,AUBURN,AL 36849
[4] OHIO STATE UNIV,COLUMBUS,OH 43210
[5] PURDUE UNIV,W LAFAYETTE,IN 47907
[6] MICHIGAN STATE UNIV,E LANSING,MI 48824
[7] UNIV GUELPH,ONTARIO VET COLL,GUELPH,ON N1G 2W1,CANADA
[8] SW VET ONCOL,TUCSON,AZ
[9] UNIV MINNESOTA,ST PAUL,MN 55108
[10] VET REFERRAL CLIN,TORONTO,ON,CANADA
[11] UNIV MISSOURI,COLUMBIA,MO
关键词
D O I
10.1111/j.1939-1676.1996.tb02031.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Forty-eight dogs with histologically confirmed appendicular osteosarcoma (OSA) entered a prospective clinical trial evaluating treatment with amputation and up to 4 doses of carboplatin given every 21 days. The median disease-free interval (DFI) was 257 days, with 31.2% of the dogs disease-free at 1 year. The median survival time was 321 days, with 35.4% of the dogs alive at 1 year. Dogs with proximal humeral OSA had shorter DFI (P = .016) and survival (P = .037) times than dogs with OSA at other locations. Dogs with lower body weights (<40 kg) had longer DFI (P = .0056) and survival (P = .007) times than larger dogs. Survival times for dogs that received carboplatin were statistically longer than those previously reported for amputation alone (P < .001). DFI and survival times are similar to those previously reported for 2 to 4 doses of cisplatin. Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m(2). Neutropenia was the dose-limiting toxicity in this study. Copyright (C) 1996 by the American College of Veterinary Internal Medicine.
引用
收藏
页码:76 / 81
页数:6
相关论文
共 49 条
  • [31] MUGGIA FM, 1989, SEMIN ONCOL, V16, P7
  • [32] OBRIEN MG, 1993, COMP CONT EDUC PRACT, V15, P939
  • [33] OGILVIE GK, 1991, J AM VET MED ASSOC, V199, P613
  • [34] OGILVIE GK, 1989, J AM VET MED ASSOC, V195, P1584
  • [35] OGILVIE GK, 1988, AM J VET RES, V49, P1076
  • [36] OZOLS RF, 1989, SEMIN ONCOL, V16, P14
  • [37] PHARMACOKINETIC AND PHASE-I EVALUATION OF CARBOPLATIN IN DOGS
    PAGE, RL
    MCENTEE, MC
    GEORGE, SL
    WILLIAMS, PL
    HEIDNER, GL
    NOVOTNEY, CA
    RIVIERE, JE
    DEWHIRST, MW
    THRALL, DE
    [J]. JOURNAL OF VETERINARY INTERNAL MEDICINE, 1993, 7 (04) : 235 - 240
  • [38] PRIESTER WA, 1980, MONOGR NATL CANC I, V54
  • [39] Probst C. W., 1982, Compendium on Continuing Education for the Practicing Veterinarian, V4, P260
  • [40] RODRIGUEZ CO, 1992, VET CANC SOC 12 ANN